NEW YORK (GenomeWeb) — French diagnostics firm Novacyt said today that its molecular testing division Primerdesign has extended its sepsis assay development contract with Immunexpress.
Specific terms of the deal were not disclosed.
Novacyt said the companies have been working together for three years, with Primerdesign providing Immunexpress with assay development services. In 2017, Seattle-based Immunexpress received US Food and Drug Administration clearance for a direct-from-blood sepsis test, and earlier this year it received a contract from the US Department of Health and Human Services to commercialize its SeptiCyte sample-to-result sepsis assay.
"Our continued partnership with Novacyt supports our joint efforts to deliver multiplexed assays that improve the management and clinical outcomes of sepsis patients around the world," Immunexpress CEO Rolland Carlson said in a statement. "We have been impressed with Primerdesign's ability to rapidly develop assays and their track record of CE marking diagnostic tests in a timely manner."